TGTX - TG Therapeutics - Stock Price & Dividends

TG Therapeutics Inc., a biopharmaceutical company, is dedicated to developing and commercializing innovative treatments for B-cell mediated diseases worldwide. The company's primary focus is on acquiring, developing, and marketing novel therapies to address unmet medical needs in this area.

One of its flagship products is BRIUMVI, an anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. This medication has the potential to significantly improve the lives of patients suffering from this debilitating condition.

TG Therapeutics has a robust development pipeline, featuring several promising investigational medicines. Umbralisib, an oral inhibitor of PI3K-delta, is being developed for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma. TG-1701, an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor, has shown selectivity to BTK in vitro kinase screening, making it a promising candidate for further development. Additionally, TG-1801, a bispecific CD47 and CD19 antibody, is another key asset in the company's pipeline.

The company has established strategic partnerships with various organizations, including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., Rhizen Pharmaceuticals, S.A., Jiangsu Hengrui Medicine Co., and Novimmune SA, to advance the development and commercialization of its pipeline assets. Furthermore, TG Therapeutics has a collaboration agreement with Checkpoint Therapeutics, Inc. to develop and commercialize anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.

Founded in 1993, TG Therapeutics Inc. is headquartered in Morrisville, North Carolina, and is committed to improving patient outcomes through its innovative approach to developing novel treatments for B-cell mediated diseases. For more information, please visit the company's website at https://www.tgtherapeutics.com.